Evicenter
P&T meetings

Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
Last updated
217 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

144 evidence topics · 47 sources

Other product development or post-marketing obligations required by the FDA
Postmarketing requirements and commitments in the FDA approval letter

No evidence found.